MENU
+Compare
GLUE
Stock ticker: NASDAQ
AS OF
Aug 11, 01:15 PM (EDT)
Price
$4.38
Change
-$0.00 (-0.00%)
Capitalization
269.41M

GLUE Monte Rosa Therapeutics Forecast, Technical & Fundamental Analysis

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins... Show more

GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for GLUE with price predictions
Aug 08, 2025

GLUE in downward trend: 10-day moving average broke below 50-day moving average on August 08, 2025

The 10-day moving average for GLUE crossed bearishly below the 50-day moving average on August 08, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 30, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on GLUE as a result. In of 74 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for GLUE turned negative on July 29, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 40 similar instances when the indicator turned negative. In of the 40 cases the stock turned lower in the days that followed. This puts the odds of success at .

GLUE moved below its 50-day moving average on August 01, 2025 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLUE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GLUE's RSI Indicator exited the oversold zone, of 23 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where GLUE advanced for three days, in of 238 cases, the price rose further within the following month. The odds of a continued upward trend are .

GLUE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 105 cases where GLUE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.005) is normal, around the industry mean (18.662). P/E Ratio (8.228) is within average values for comparable stocks, (54.033). GLUE's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.909). Dividend Yield (0.000) settles around the average of (0.049) among similar stocks. P/S Ratio (2.030) is also within normal values, averaging (286.048).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. GLUE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLUE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
GLUE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

GLUE is expected to report earnings to rise 5.56% to -37 cents per share on November 06

Monte Rosa Therapeutics GLUE Stock Earnings Reports
Q3'25
Est.
$-0.38
Q2'25
Beat
by $0.02
Q1'25
Beat
by $1.01
Q4'24
Missed
by $0.54
Q3'24
Beat
by $0.18
The last earnings report on August 07 showed earnings per share of -35 cents, beating the estimate of -37 cents. With 83.34K shares outstanding, the current market capitalization sits at 269.41M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
321 Harrison Avenue
Phone
+1 617 949-2643
Employees
133
Web
https://www.monterosatx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SCGLF63.84N/A
N/A
Societe Generale
MNXBF5.38N/A
N/A
Monex Group, Inc.
NRXXY13.15N/A
N/A
NORDEX SE
CRTAF12.35N/A
N/A
Cartica Acquisition Corp.
BBOE0.65N/A
N/A
Black Box Entertainment Ltd.

GLUE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, GLUE has been loosely correlated with EYPT. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if GLUE jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GLUE
1D Price
Change %
GLUE100%
+3.55%
EYPT - GLUE
46%
Loosely correlated
N/A
IMNM - GLUE
43%
Loosely correlated
-1.82%
DNLI - GLUE
42%
Loosely correlated
-1.90%
ATXS - GLUE
42%
Loosely correlated
-6.15%
NRIX - GLUE
40%
Loosely correlated
-2.28%
More